{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:24:03Z","timestamp":1788269043149,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"DOI":"10.1007\/s00595-026-03476-w","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:11:08Z","timestamp":1788268268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of tolvaptan sodium phosphate in patients undergoing open-heart surgery"],"prefix":"10.1007","author":[{"given":"Hiroyuki","family":"Nishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Nakagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Iha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"3476_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00392-014-0754-7","volume":"104","author":"V Simopoulos","year":"2015","unstructured":"Simopoulos V, Tagarakis G, Hatziefthimiou A, Skoularigis I, Triposkiadis F, Trantou V, et al. Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study. Clin Res Cardiol. 2015;104:31\u20137.","journal-title":"Clin Res Cardiol"},{"key":"3476_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0003-4975(99)01298-9","volume":"69","author":"S Sirivella","year":"2000","unstructured":"Sirivella S, Gielchinsky I, Parsonnet V. Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. Ann Thorac Surg. 2000;69:501\u20136.","journal-title":"Ann Thorac Surg"},{"key":"3476_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jacc.2011.03.056","volume":"58","author":"A Sezai","year":"2011","unstructured":"Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Results of lowdose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NUHIT (Nihon University working group study of low-dose HANP infusion therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol. 2011;58:897\u2013903.","journal-title":"J Am Coll Cardiol"},{"key":"3476_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/eurheartj\/ehu484","volume":"36","author":"SD Anker","year":"2015","unstructured":"Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015;36:715\u201323.","journal-title":"Eur Heart J"},{"key":"3476_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jacc.2006.10.048","volume":"49","author":"RM Mentzer Jr","year":"2007","unstructured":"Mentzer RM Jr, Oz MC, Sladen RN, Graeve AH, Hebeler RF Jr, Luber JM Jr, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial. J Am Coll Cardiol. 2007;49:716\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"3476_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"3476_CR7","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1210\/en.2004-1590","volume":"146","author":"T Miyazaki","year":"2005","unstructured":"Miyazaki T, Yamamura Y, Onogawa T, Nakamura S, Kinoshita S, Nakayama S, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology. 2005;146:3037\u20138.","journal-title":"Endocrinology"},{"key":"3476_CR8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00595-015-1251-y","volume":"45","author":"H Nishi","year":"2015","unstructured":"Nishi H, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Kawamura M, et al. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial. Surg Today. 2015;45:1542\u201351.","journal-title":"Surg Today"},{"key":"3476_CR9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1253\/circj.CJ-17-0967","volume":"82","author":"Y Kishimoto","year":"2018","unstructured":"Kishimoto Y, Nakamura Y, Harada S, Onohara T, Kishimoto S, Kurashiki T, et al. Can tolvaptan protect renal function in the early postoperative period of cardiac surgery?- results of a single-center randomized controlled study. Circ J. 2018;82:999\u20131007.","journal-title":"Circ J"},{"key":"3476_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00595-016-1406-5","volume":"47","author":"M Yamada","year":"2017","unstructured":"Yamada M, Nishi H, Sekiya N, Horikawa K, Takahashi T, Sawa Y. The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery. Surg Today. 2017;47:498\u2013505.","journal-title":"Surg Today"},{"key":"3476_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jjcc.2019.12.010","volume":"75","author":"H Nishi","year":"2020","unstructured":"Nishi H. Advent of new perioperative care for fluid management after cardiovascular surgery: a review of current evidence. J Cardiol. 2020;75:606\u201313.","journal-title":"J Cardiol"},{"key":"3476_CR12","doi-asserted-by":"crossref","unstructured":"Sato N, Uno S, Yamasaki Y, Hirano T, Kim S, on behalf of the OPC-61815 Investigators. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients with Congestive Heart Failure\u2014A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial. Circ. J Off J Jpn Circ Soc. 2022;86:699\u2013708.","DOI":"10.1253\/circj.CJ-21-0430"},{"key":"3476_CR13","doi-asserted-by":"crossref","unstructured":"Sato N, Uno S, Kurita Y, Kim S, the OPTION-HF Investigators. Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure. ESC Heart Fail. 2022;9:3275\u20133286.","DOI":"10.1002\/ehf2.14021"},{"key":"3476_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030720","volume":"13","author":"M Nakamura","year":"2024","unstructured":"Nakamura M, Imamura T, Kinugawa K. Preliminary report of intravenous tolvaptan sodium phosphate (Samtas()) treatment in decompensated heart failure. J Clin Med. 2024;13:720.","journal-title":"J Clin Med"},{"key":"3476_CR15","first-page":"176","volume":"27","author":"M Nakamura","year":"2023","unstructured":"Nakamura M, Imamura T, Wakakuri E, Onoda H, Ushijima R, Kinugawa K. Initial clinical experience of intravenous tolvaptan sodium phosphate in patients with congestive heart failure. J Cardiol Cases. 2023;27:176\u20139.","journal-title":"J Cardiol Cases"},{"key":"3476_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.athoracsur.2014.07.038","volume":"99","author":"H Miyata","year":"2015","unstructured":"Miyata H, Tomotaki A, Motomura N, Takamoto S. Operative mortality and complication risk model for all major cardiovascular operations in Japan. Ann Thorac Surg. 2015;99:130\u20139.","journal-title":"Ann Thorac Surg"},{"key":"3476_CR17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1253\/circj.CJ-21-0926","volume":"86","author":"K Kinugawa","year":"2022","unstructured":"Kinugawa K, Nakata E, Hirano T, Kim S. Tolerability of the intravenously administered tolvaptan prodrug, OPC-61815, in patients with congestive heart failure who have difficulty with, or are incapable of, oral intake (TRITON-HF)\u2014a phase III, multicenter, open-label trial. Circ J. 2022;86:1068\u201378.","journal-title":"Circ J"},{"key":"3476_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2016.06.156","volume":"220","author":"K Matsuyama","year":"2016","unstructured":"Matsuyama K, Koizumi N, Nishibe T, Iwasaki T, Iwahasi T, Toguchi K, et al. Effects of short-term administration of tolvaptan after open heart surgery. Int J Cardiol. 2016;220:192\u20135.","journal-title":"Int J Cardiol"},{"key":"3476_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11748-016-0712-6","volume":"65","author":"T Kido","year":"2017","unstructured":"Kido T, Nishi H, Toda K, Ueno T, Kuratani T, Sakaki M, et al. Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery. Gen Thorac Cardiovasc Surg. 2017;65:110\u20136.","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"3476_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13730-020-00518-1","volume":"10","author":"K Kakeshita","year":"2021","unstructured":"Kakeshita K, Koike T, Imamura T, Fujioka H, Yamazaki H, Kinugawa K. Expression of aquaporin-2 in the collecting duct and responses to tolvaptan. CEN Case Rep. 2021;10:69\u201373.","journal-title":"CEN Case Rep"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03476-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-026-03476-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03476-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:11:09Z","timestamp":1788268269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-026-03476-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":20,"alternative-id":["3476"],"URL":"https:\/\/doi.org\/10.1007\/s00595-026-03476-w","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflict of interest in this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective observational study was approved by the Institutional Review Board of the NHO Osaka National Hospital (IRB no. 23032) and was conducted in accordance with the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1964 and later versions.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived because of the retrospective design of the study. Patient consent for participation was obtained using an opt-out method.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":4,"name":"Ethics","label":"Registration No. of the study","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":5,"name":"Ethics","label":"Animal studies","group":{"name":"EthicsHeading","label":"Declarations"}}]}}